门冬胰岛素注射液联合甘精胰岛素注射液对新诊断2型糖尿病患者血糖控制及胰岛功能的影响(1)
[摘要] 目的 分析门冬胰岛素注射液联合甘精胰岛素注射液对新诊断2型糖尿病患者血糖控制及胰岛功能的影响。方法 选取2017年6月—2019年5月该院78例新诊断2型糖尿病患者，依照治疗方案不同分组，各39例。对照组采用精蛋白重组人胰岛素注射液治疗，观察组采用门冬胰岛素注射液+甘精胰岛素注射液治疗，比较两组血糖水平、胰岛功能、低血糖发生率。结果 治疗后，观察组空腹血糖、餐后2 h血糖低于对照组(P<0.05);治疗后，观察组胰岛素分泌指数高于对照组，胰岛素抵抗指数低于对照组(P<0.05);观察组低血糖发生率5.13%较对照组20.51%低(P<0.05)。 结论 门冬胰岛素注射液联合甘精胰岛素注射液治疗新诊断2型糖尿病，能有效控制患者血糖水平，调节胰岛功能。
[关键词] 门冬胰岛素;甘精胰岛素;新诊断2型糖尿病;血糖;胰岛功能
[中图分类号] R587.2 [文献标识码] A [文章编号] 1672-4062(2020)06(b)-0070-03
[Abstract] Objective To analyze the effect of insulin aspart injection combined with insulin glargine injection on blood glucose control and islet function in newly diagnosed type 2 diabetes patients. Methods Seventy-eight patients with newly diagnosed type 2 diabetes from June 2017 to May 2019 in the hospital were selected and divided into 39 groups according to different treatment plans. The control group was treated with protamine recombinant human insulin injection， and the observation group was treated with insulin aspart injection + insulin glargine injection. The blood glucose level， islet function and incidence of hypoglycemia were compared between the two groups. Results After treatment， the fasting blood glucose in the observation group and the blood glucose at 2 hours after the meal were lower than that in the control group (P<0.05); The incidence of hypoglycemia in the group was 5.13% lower than that in the control group 20.51%(P<0.05). Conclusion Insulin aspart injection combined with insulin glargine injection in the treatment of newly diagnosed type 2 diabetes can effectively control the blood glucose level of patients and regulate the function of islets.
[Key words] Insulin aspart; Insulin glargine; Newly diagnosed type 2 diabetes; Blood glucose; Islet function
2型糖尿病与I型糖尿病一样，具有遗传倾向，是由遗传、环境、生活方式、年龄等因素导致的疾病。数据资料显示，我国成年人糖尿病约有1.139亿人，患病率为11.6%，其中，2型糖尿病居多，占糖尿病患者80%～90%[1-2]。研究报道，新诊断2型糖尿病患者发病时间较短，尚未出现肾、心、脑、血管等方面的并发症，此时加以干预，不仅能有效控制患者血糖水平，还能逆转新诊断2型糖尿病患者部分胰岛β细胞功能，改善胰岛素抵抗，从而改善胰岛功能[3]。早期对初诊断2型糖尿病患者进行胰岛素干预，能有效地控制患者血糖水平，控制疾病进展。目前，临床治疗2型糖尿病已逐渐向早期强化胰岛素治疗为主。基于此，该研究选取2017年6月—2019年5月该院78例新诊断2型糖尿病患者，旨在分析门冬胰岛素注射液联合甘精胰岛素注射液的治疗效果，现报道如下。
1 资料与方法
1.1 一般资料
选取该院伦理委员会审核批准的78例新诊断2型糖尿病患者，依照治疗方案不同分组，各39例。对照组男21例，女18例;年龄40～76岁，平均(57.91±8.74)岁;病程1～10个月，平均(5.62±2.07)个月。观察组男20例，女19例;年龄40～74岁，平均(56.73±8.16)岁;病程1～12个月，平均(6.17±2.54)个月，两组性别、年龄、病程差异无统计学意义(P>0.05)，均衡可比。
1.2 納入及排除标准, 百拇医药(孙静)
[关键词] 门冬胰岛素;甘精胰岛素;新诊断2型糖尿病;血糖;胰岛功能
[中图分类号] R587.2 [文献标识码] A [文章编号] 1672-4062(2020)06(b)-0070-03
[Abstract] Objective To analyze the effect of insulin aspart injection combined with insulin glargine injection on blood glucose control and islet function in newly diagnosed type 2 diabetes patients. Methods Seventy-eight patients with newly diagnosed type 2 diabetes from June 2017 to May 2019 in the hospital were selected and divided into 39 groups according to different treatment plans. The control group was treated with protamine recombinant human insulin injection， and the observation group was treated with insulin aspart injection + insulin glargine injection. The blood glucose level， islet function and incidence of hypoglycemia were compared between the two groups. Results After treatment， the fasting blood glucose in the observation group and the blood glucose at 2 hours after the meal were lower than that in the control group (P<0.05); The incidence of hypoglycemia in the group was 5.13% lower than that in the control group 20.51%(P<0.05). Conclusion Insulin aspart injection combined with insulin glargine injection in the treatment of newly diagnosed type 2 diabetes can effectively control the blood glucose level of patients and regulate the function of islets.
[Key words] Insulin aspart; Insulin glargine; Newly diagnosed type 2 diabetes; Blood glucose; Islet function
2型糖尿病与I型糖尿病一样，具有遗传倾向，是由遗传、环境、生活方式、年龄等因素导致的疾病。数据资料显示，我国成年人糖尿病约有1.139亿人，患病率为11.6%，其中，2型糖尿病居多，占糖尿病患者80%～90%[1-2]。研究报道，新诊断2型糖尿病患者发病时间较短，尚未出现肾、心、脑、血管等方面的并发症，此时加以干预，不仅能有效控制患者血糖水平，还能逆转新诊断2型糖尿病患者部分胰岛β细胞功能，改善胰岛素抵抗，从而改善胰岛功能[3]。早期对初诊断2型糖尿病患者进行胰岛素干预，能有效地控制患者血糖水平，控制疾病进展。目前，临床治疗2型糖尿病已逐渐向早期强化胰岛素治疗为主。基于此，该研究选取2017年6月—2019年5月该院78例新诊断2型糖尿病患者，旨在分析门冬胰岛素注射液联合甘精胰岛素注射液的治疗效果，现报道如下。
1 资料与方法
1.1 一般资料
选取该院伦理委员会审核批准的78例新诊断2型糖尿病患者，依照治疗方案不同分组，各39例。对照组男21例，女18例;年龄40～76岁，平均(57.91±8.74)岁;病程1～10个月，平均(5.62±2.07)个月。观察组男20例，女19例;年龄40～74岁，平均(56.73±8.16)岁;病程1～12个月，平均(6.17±2.54)个月，两组性别、年龄、病程差异无统计学意义(P>0.05)，均衡可比。
1.2 納入及排除标准, 百拇医药(孙静)